Immunocore Holdings Plc (IMCR) - News Archive

Immunocore Presents Phase 1 Data for Hepatitis B Candidate at AASLD s The Liver Meeting In an era marked by remarkable advances in therapeutic strategies, Immunocore has taken a significant step forward in the battle ag...

Uveal melanoma (UM) is the most common primary intraocular malignancy, characterized by its aggressive nature and propensity for metastasis. Annually, approximately 1,500 to 2,500 new cases are diagnosed in the United S...

In the fast-paced world of biopharmaceutical innovation, Immunocore Holdings Plc continues to forge ahead with promising research endeavors, despite facing formidable competition on multiple fronts. A notable developmen...

Immunocore Holdings Plc (NASDAQ: IMCR) has announced a significant milestone in cancer treatment as it has finalized a reimbursement agreement in England for its innovative therapy, KIMMTRAK, aimed at HLA-A 02:01-positi...

Immunocore Holdings Plc has marked a significant milestone in the realm of cancer therapies, as the company recently presented encouraging Phase 1 data on brenetafusp, a novel ImmTAC (Immune Mobilizing Monoclonal T cell...